TriSalus Q2 2026 Earnings: Gross Margin Rises as Operating Loss Widens

TriSalus Life Sciences (Nasdaq: TLSI) reported Q2 2026 revenue of $11.4 million, up 1.7% from $11.2 million a year earlier, while diluted loss per share narrowed to $0.16 from $0.27. Gross margin improved on lower TriNav unit costs, but expanded sales and marketing spending pushed the operating loss to $9.8 million and the adjusted EBITDA loss to $7.1 million.

Core financial results

TriNav revenue was nearly flat year over year, but lower cost per unit lifted gross profit by 5.2% and expanded gross margin by 2.9 percentage points. That improvement was not enough to offset the cost of expanding the commercial organization.

Operating and adjusted EBITDA losses both widened by approximately 34%. Net loss attributable to common stockholders increased more modestly, while the per-share loss narrowed partly because the weighted average share count was substantially higher.

Adjusted EBITDA is a non-GAAP measure that excludes items including interest, taxes, depreciation, stock-based compensation and changes in the fair value of certain liabilities.

Commercial expansion widened losses despite better unit economics

Lower cost per TriNav unit improved gross margin, but the resulting increase in gross profit was small relative to the additional commercial spending. Sales and marketing expense rose approximately 59% to $11.4 million from $7.2 million as TriSalus invested in marketing and expanded its sales organization.

Research and development expense declined to $3.1 million from $3.7 million, while general and administrative expense fell to $5.2 million from $5.9 million. Those savings did not offset the $4.3 million increase in sales and marketing expense, resulting in a $2.5 million increase in operating loss.

Below the operating line, the quarter included $1.6 million of non-cash net gains related to changes in the fair value of derivative liabilities, compared with $0.4 million a year earlier. The narrower loss per share also reflected an approximately 77% increase in weighted average shares to 58.3 million, rather than an improvement in aggregate net income.

Cash flow and balance sheet

TriSalus used $16.6 million of cash in operating activities during the first six months of 2026, up from $11.8 million in the comparable 2025 period. These are six-month figures and should not be treated as quarterly cash flow.

Cash and cash equivalents reached $46.3 million at June 30, 2026, compared with $20.4 million at the end of 2025. The increase was primarily supported by an equity offering that generated $46.0 million in gross proceeds and $42.6 million in net proceeds during the first quarter. Management believes the proceeds provide sufficient runway to fund commercial expansion and pipeline development.

Long-term debt remained approximately unchanged at $33.1 million, while Q2 interest expense was $1.5 million. Common shares outstanding increased to 61.5 million from 50.0 million at year-end, reflecting the dilution associated with the equity financing. Inventory also rose to $4.2 million from $3.1 million over the same period.

2026 guidance

TriSalus maintained its full-year revenue range, leaving the outlook unchanged from the guidance established in the first quarter. The range represents company-projected growth of 19% to 26% over 2025.

With first-half revenue of $20.3 million, the guidance implies approximately $33.7 million to $36.7 million of second-half revenue. Achieving the range therefore depends on a meaningful acceleration as the expanded sales organization ramps its efforts.

Management commentary

CEO Mary Szela said the company expects further growth in the second half as its sales team continues to ramp. Management continues to view the long-term growth opportunity for the Pressure-Enabled Drug Delivery platform as substantial.

TriSalus also highlighted CMS’s establishment of a G-code extending reimbursement for vascular embolization procedures using a pressure-generating catheter into physician office-based laboratories. The reimbursement rate is still being finalized, so the eventual commercial economics are not yet known.

On the clinical side, the company submitted data from the multicenter, randomized PEDIR study for publication. The study evaluated tumor-to-normal delivery ratios in hepatocellular carcinoma and hypovascular tumors.

Recent insider transactions

The provided insider dataset shows 2,627,346 shares purchased across 23 transactions and 34,223 shares sold across six transactions over the last six months, resulting in net purchases of 2,593,123 shares. The latest 10 reported transactions include five purchases, one sale and four stock awards; stock awards should be distinguished from open-market transactions.

Risks investors should monitor

• Back-half revenue concentration: Full-year guidance implies approximately $33.7 million to $36.7 million of second-half revenue, well above the $20.3 million generated in the first half.
• Spending ahead of revenue growth: Q2 revenue increased only 1.7%, while sales and marketing expense rose approximately 59%, widening both operating and adjusted EBITDA losses.
• Cash burn and dilution: First-half operating cash use increased to $16.6 million. The cash balance was strengthened by an equity offering that also increased the number of shares outstanding.
• Reimbursement uncertainty: CMS has established the relevant G-code, but the reimbursement rate has not been finalized, leaving the financial effect uncertain.
• Clinical and development risk: PEDIR data have been submitted for publication, while nelitolimod remains investigational and the company is still exploring development partnerships.

Summary

TriSalus improved TriNav unit economics and gross margin in Q2 2026, but near-flat revenue growth did not absorb the higher cost of commercial expansion. The equity offering strengthened liquidity, although operating cash use and the share count increased. The main operating test for the remainder of 2026 is whether the larger sales organization can deliver the substantial second-half revenue acceleration implied by unchanged guidance.